275 related articles for article (PubMed ID: 31696801)
1. Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug.
Bergmann MM; Caubet JC
Curr Pharm Des; 2019; 25(36):3872-3880. PubMed ID: 31696801
[TBL] [Abstract][Full Text] [Related]
2. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
3. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
Barbaud A; Castagna J; Soria A
Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
[TBL] [Abstract][Full Text] [Related]
4. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions.
Guvenir H; Arikoglu T; Vezir E; Misirlioglu ED
Curr Pharm Des; 2019; 25(36):3840-3854. PubMed ID: 31696807
[TBL] [Abstract][Full Text] [Related]
5. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
6. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
Paulmann M; Mockenhaupt M
Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
[TBL] [Abstract][Full Text] [Related]
7. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
[TBL] [Abstract][Full Text] [Related]
8. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
9. Making a diagnosis in severe cutaneous drug hypersensitivity reactions.
Ardern-Jones MR; Mockenhaupt M
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):283-293. PubMed ID: 31247634
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis.
Romano A; Caubet JC
J Allergy Clin Immunol Pract; 2014; 2(1):3-12. PubMed ID: 24565763
[TBL] [Abstract][Full Text] [Related]
12. [The major SCAR syndromes].
Piérard GE; Lesuisse M; Piérard-Franchimont C
Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
[TBL] [Abstract][Full Text] [Related]
13. Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions.
Copaescu AM; Ben-Shoshan M; Trubiano JA
Front Med (Lausanne); 2022; 9():923991. PubMed ID: 36313986
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan.
Huang YS; Wu CY; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH
Liver Int; 2021 Nov; 41(11):2671-2680. PubMed ID: 34153177
[TBL] [Abstract][Full Text] [Related]
15. [Drug reaction with eosinophilia and systemic symptoms].
Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
[TBL] [Abstract][Full Text] [Related]
16. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
17. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
18. Differential cytokine profiles produced by anti-epileptic drug re-exposure of peripheral blood mononuclear cells derived from severe anti-epileptic drug patients and non-allergic controls.
Srinoulprasert Y; Kumkamthornkul P; Tuchinda P; Wongwiangjunt S; Sathornsumetee S; Jongjaroenprasert K; Kulthanan K
Cytokine; 2022 Sep; 157():155951. PubMed ID: 35772364
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a lymphocyte transformation test and cytokine detection assay to identify phenytoin and carbamazepine provoked DRESS or SJS/TEN in epilepsy patients.
Kumkamthornkul P; Udnaen S; Tansit T; Tuchinda P; Srinoulprasert Y
Int Immunopharmacol; 2018 Oct; 63():204-210. PubMed ID: 30103195
[TBL] [Abstract][Full Text] [Related]
20. An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions.
Gelincik A; Cavkaytar O; Kuyucu S
Curr Pharm Des; 2019; 25(36):3881-3901. PubMed ID: 31692425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
